INAB (IN8bio Inc.) יתרות מזומנים למניה

סמלים רשמיים של חברת IN8bio (INAB)

High R&D expenditures associated with expanding the drug pipeline are increasing current expenses for IN8bio, Inc. (INAB). Cash per share demonstrates financial stability, with 1.29 becoming the new value for this metric. Business protection is secured by patents for T-cell modification, while the development of therapies for complex tumors relies on a strategic alliance with specialized hospitals.

כמות מזומנים למניה: IN8bio (INAB) עבור 04.07.2022 - 20.11.2026

פילוחי מדדים ואנליטיקה של חברת in8bio.com (INAB)

- מחיר ותחזית קונצנזוס למחירים:
- מדדי הערכת שווי שוק של העסק:
- נתוני יתרות מזומנים ותזרימי מזומנים:
ניתוח כללי של החברה:INAB IN8bio, Inc.
פריט של המותג IN8bio, Inc.

Cash per share reflects the issuer's actual financial autonomy, excluding subjective market expectations. By analyzing the cash per share trend, an investor assesses the balance between the margin of safety and the risk of inefficient liquidity utilization. This metric measures the actual value of available capital on a per-share basis. For IN8bio, Inc. (INAB), this is a critical indicator of the ability to fund costly clinical trials for anti-cancer cell therapies. Sufficient resources guarantee the scalability of laboratory processes until recognition is achieved within the oncology community.